Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Optimizing Y90 Therapy for Radiation Lobectomy

NCT: NCT04390724 · RECRUITING

NCT IDNCT04390724
StatusRECRUITING
Start Date2020-07-17
Completion2026-07

Brief Summary

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

Frequently Asked Questions

What is Optimizing Y90 Therapy for Radiation Lobectomy?

Optimizing Y90 Therapy for Radiation Lobectomy is a clinical trial registered under NCT04390724. Current status: RECRUITING.

What is the status of NCT04390724?

The current status of NCT04390724 (Optimizing Y90 Therapy for Radiation Lobectomy) is: RECRUITING.

When did Optimizing Y90 Therapy for Radiation Lobectomy start?

Optimizing Y90 Therapy for Radiation Lobectomy started on 2020-07-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.